The Latest Cardiac and Vascular News
MENLO PARK, Calif., June 22, 2021 /PRNewswire/ — Ablacon, Inc., developer of an advanced mapping system to guide the treatment of atrial fibrillation (AF), announced today that is has promoted Martin Grasse to the position of Chief Executive Officer. Former CEO Duke Rohlen will continue with the company as Executive Chairman. “Marty has demonstrated exceptional leadership capabilities […]
– Genetics allows the study of risk related to hereditary cardiovascular disease, with special relevance in cardiomyopathies, arrhythmias and vascular involvement syndromes that may involve risk of sudden death. – The myCardio service designed by Veritas Intercontinental, a company focused on the study of genetic predisposition, includes all genes recommended […]
Cell Therapy Platform Demonstrates High Dose CD34+ Cell Performance Characteristics in Patients with Ischemic Heart Failure SAN CARLOS, Calif., June 22, 2021 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces data from its CardiAMP […]
BOSTON–(BUSINESS WIRE)–Imbria Pharmaceuticals, a clinical stage biopharmaceutical company developing novel therapies designed to enhance cellular energetics for the treatment of major forms of heart disease and specific inborn errors of metabolism, today announced that the first 10 (ten) patients were dosed in the IMPROVE-DiCE Phase 2a, open-label study of IMB-1018972 […]
Leading provider of wearable device-derived health data partners with vascular health-tech firm to provide industry-leading health insights for clinical and other users ATLANTA, June 21, 2021 /PRNewswire/ — LifeQ, the world’s preeminent provider of biometrics and health information derived from wearable devices, has partnered with CONNEQT, Inc, a consumer health company offering home […]
SAN CARLOS, Calif., June 21, 2021 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the European patent office has issued a Decision to Grant European Patent No. 3593810 to BioCardia with publication on June 23, 2021. […]
– This new indication is based on the EMPEROR-Reduced trial, which showed a significant 25 percent reduction in the combined relative risk versus placebo of cardiovascular death or hospitalization for heart failure with reduced ejection fraction in adults with or without diabetes and an eGFR of ≥20ml/min/1.73 m2 – Heart failure […]
VANCOUVER and MINNEAPOLIS, June 18, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced the publication of an article entitled, “Safety and Efficacy of Coronary Sinus Narrowing in Chronic Refractory Angina: Insights from the RESOURCE Study” in the International Journal of Cardiology. The article, authored by Francesco […]
PORTLAND, Ore., June 17, 2021 /PRNewswire/ — VisCardia Inc., a privately held medical device developer, announced today it has been selected to participate in MedTech Innovator’s Annual Showcase and Accelerator Program. The selection process reduced 1,100 applicants from over 50 countries to 195 candidate companies that presented their technology to teams of senior […]
SAN DIEGO and PARIS, June 17, 2021 (GLOBE NEWSWIRE) — Rancho Santa Fe Bio, Inc. (“RSF Bio” or the “Company”), a San Diego, California-based clinical-stage cardiovascular platform company, today announced that it has entered into an exclusive worldwide license agreement with Sanofi, a global biopharmaceutical company. This agreement provides RSF […]
